When does Yervoy’s patent expire, and what does that usually mean for price?
When a branded cancer drug’s patent(s) expire, manufacturers generally lose market exclusivity and face competition from biosimilars or other lower-cost entrants. That competition often pushes prices down, especially for countries that require price cuts or negotiate pricing with payers as exclusivity ends. The exact impact depends on what type of patent is expiring (composition-of-matter, formulation, method-of-use, etc.), what exclusivities are still in force, and whether biosimilars launch quickly.
Because the question is about pricing specifically, the timing and scope matter: a patent expiration that does not remove all forms of exclusivity (or is followed by additional patent coverage) can delay meaningful pricing pressure.
Will biosimilars to Yervoy enter right after patent expiry?
Patent expiry alone does not guarantee immediate biosimilar availability. Even after some patents expire, companies may still litigate other patents, and regulatory review and manufacturing scale-up can delay launches. If biosimilar products do not enter quickly or remain limited, the brand may hold pricing better than expected.
Pricing pressure is strongest when multiple biosimilar competitors launch and payers can switch patients (or at least gain access to the cheaper option) without major clinical or administrative barriers.
What pricing effects can patients and insurers typically see?
If biosimilars (or other competitors) enter, payers often respond with one or more of these approaches:
- Negotiated price reductions for the originator product to maintain formulary position
- Step therapy, prior authorization tightening, or preferred formulary status for the cheaper product
- Use of biosimilar substitution policies where allowed
- Changes in patient out-of-pocket costs depending on coverage tiering and coinsurance rules
Patients might see more changes through insurance approvals and cost-sharing than through headline list prices, since many countries and plans already negotiate discounts.
Could Yervoy’s price keep rising even after patent expiry?
Yes. Patent expiry does not automatically produce lower real-world costs if other factors counteract it, such as:
- Continued exclusivity not tied to the specific patents expiring (regulatory/market exclusivity blocks)
- Ongoing litigation that delays biosimilar entry
- Strong demand for the brand with limited switching in practice
- Price increases unrelated to patent status (for example, new indications, reimbursement changes, or broad annual list-price adjustments)
In practice, originator pricing may fall after biosimilar entry, but the size and timing of that drop vary widely.
What determines the size of the post-expiration price drop?
The magnitude of pricing impact usually depends on:
- How many competitors launch and how quickly they gain formulary access
- Payer incentives to switch (and whether switching is permitted for stable patients)
- Country-by-country reimbursement rules and negotiation mechanisms
- Whether originator manufacturers continue to offer rebates and contracting discounts to preserve share
Are there signals that pricing pressure is likely?
Even without exact figures, the most reliable signals tend to be regulatory activity (biosimilar approvals/filings), manufacturer communications about forthcoming launches, and payer policy updates around interchangeability/substitution rules. When those signals line up with the end of exclusivity, pricing changes tend to become noticeable in contracts and reimbursement policy first.
---
Sources
I don’t have the specific Yervoy patent expiration date(s) or the governing jurisdictions you care about in the provided information, so I can’t state a timeline or forecast magnitude without risking inaccuracy. If you share the country (e.g., US/EU/UK) or the specific patent/exclusivity you mean, I can translate that into the most likely pricing impact for that market.